Target Specific De Novo Design of Drug Candidate Molecules with Graph Transformer-based Generative Adversarial Networks

• URL: http://arxiv.org/abs/2302.07868v7
• Date: Mon, 26 May 2025 12:04:26 GMT
• Title: Target Specific De Novo Design of Drug Candidate Molecules with Graph Transformer-based Generative Adversarial Networks
• Authors: Atabey Ünlü, Elif Çevrim, Melih Gökay Yiğit, Ahmet Sarıgün, Hayriye Çelikbilek, Osman Bayram, Deniz Cansen Kahraman, Abdurrahman Olğaç, Ahmet Sureyya Rifaioğlu, Erden Banoğlu, Tunca Doğan,
• Abstract summary: We propose an end to end generative system, DrugGEN, for the de novo design of drug candidate molecules.<n>The system is trained using a large dataset of drug like compounds and target specific bioactive molecules.<n>It is possible to easily train models for other druggable proteins, given a dataset of experimentally known bioactive molecules.
• Score: 0.0
• License: http://creativecommons.org/licenses/by-nc-sa/4.0/
• Abstract: Discovering novel drug candidate molecules is one of the most fundamental and critical steps in drug development. Generative deep learning models, which create synthetic data given a probability distribution, offer a high potential for designing de novo molecules. However, to be utilisable in real life drug development pipelines, these models should be able to design drug like and target centric molecules. In this study, we propose an end to end generative system, DrugGEN, for the de novo design of drug candidate molecules that interact with intended target proteins. The proposed method represents molecules as graphs and processes them via a generative adversarial network comprising graph transformer layers. The system is trained using a large dataset of drug like compounds and target specific bioactive molecules to design effective inhibitory molecules against the AKT1 protein, which is critically important in developing treatments for various types of cancer. We conducted molecular docking and dynamics to assess the target centric generation performance of the model, as well as attention score visualisation to examine model interpretability. In parallel, selected compounds were chemically synthesised and evaluated in the context of in vitro enzymatic assays, which identified two bioactive molecules that inhibited AKT1 at low micromolar concentrations. These results indicate that DrugGEN's de novo molecules have a high potential for interacting with the AKT1 protein at the level of its native ligands. Using the open access DrugGEN codebase, it is possible to easily train models for other druggable proteins, given a dataset of experimentally known bioactive molecules.

Related papers

• FARM: Functional Group-Aware Representations for Small Molecules [55.281754551202326]
  We introduce Functional Group-Aware Representations for Small Molecules (FARM)<n>FARM is a novel model designed to bridge the gap between SMILES, natural language, and molecular graphs.<n>We evaluate FARM on the MoleculeNet dataset, where it achieves state-of-the-art performance on 11 out of 13 tasks.
  arXiv  Detail & Related papers  (2024-10-02T23:04:58Z)
• Cell Morphology-Guided Small Molecule Generation with GFlowNets [41.8027680592766]
  We propose an unsupervised multimodal joint embedding to define a latent similarity as a reward for GFlowNets. The proposed model learns to generate new molecules that could produce phenotypic effects similar to those of the given image target. We demonstrate that the proposed method generates molecules with high morphological and structural similarity to the target, increasing the likelihood of similar biological activity.
  arXiv  Detail & Related papers  (2024-08-09T17:40:35Z)
• Regressor-free Molecule Generation to Support Drug Response Prediction [83.25894107956735]
  Conditional generation based on the target IC50 score can obtain a more effective sampling space. Regressor-free guidance combines a diffusion model's score estimation with a regression controller model's gradient based on number labels.
  arXiv  Detail & Related papers  (2024-05-23T13:22:17Z)
• STRIDE: Structure-guided Generation for Inverse Design of Molecules [0.24578723416255752]
  $textbfSTRIDE$ is a generative molecule workflow that generates novel molecules with an unconditional generative model guided by known molecules without any retraining. Our generated molecules have on average 21.7% lower synthetic accessibility scores and also reduce ionization potential by 5.9% of generated molecules via guiding.
  arXiv  Detail & Related papers  (2023-11-06T08:22:35Z)
• DiffDTM: A conditional structure-free framework for bioactive molecules generation targeted for dual proteins [35.72694124335747]
  DiffDTM is a conditional structure-free deep generative model based on a diffusion model for dual targets based molecule generation. We have conducted comprehensive multi-view experiments to demonstrate that DiffDTM can generate drug-like, synthesis-accessible, novel, and high-binding affinity molecules. The experimental results indicate that DiffDTM can be easily plugged into unseen dual targets to generate bioactive molecules.
  arXiv  Detail & Related papers  (2023-06-24T13:08:55Z)
• Learning Subpocket Prototypes for Generalizable Structure-based Drug Design [17.61987808099346]
  Deep generative models have achieved remarkable success in generating 3D molecules conditioned on the protein pocket. Most existing methods consider molecular generation for protein pockets independently. We propose a novel method DrugGPS for generalizable structure-based drug design.
  arXiv  Detail & Related papers  (2023-05-22T13:49:49Z)
• Energy-based Generative Models for Target-specific Drug Discovery [7.509129971169722]
  We develop an energy-based probabilistic model for computational target-specific drug discovery. Results show that our proposed TagMol can generate molecules with similar binding affinity scores as real molecules.
  arXiv  Detail & Related papers  (2022-12-05T16:41:36Z)
• Drug-target affinity prediction method based on consistent expression of heterogeneous data [0.0]
  We propose a method for predicting drug-target binding affinity using deep learning models. The proposed model demonstrates its accuracy and effectiveness in predicting drug-target binding affinity on the DAVIS and KIBA datasets.
  arXiv  Detail & Related papers  (2022-11-13T02:58:03Z)
• Tailoring Molecules for Protein Pockets: a Transformer-based Generative Solution for Structured-based Drug Design [133.1268990638971]
  De novo drug design based on the structure of a target protein can provide novel drug candidates. We present a generative solution named TamGent that can directly generate candidate drugs from scratch for a given target.
  arXiv  Detail & Related papers  (2022-08-30T09:32:39Z)
• Retrieval-based Controllable Molecule Generation [63.44583084888342]
  We propose a new retrieval-based framework for controllable molecule generation. We use a small set of molecules to steer the pre-trained generative model towards synthesizing molecules that satisfy the given design criteria. Our approach is agnostic to the choice of generative models and requires no task-specific fine-tuning.
  arXiv  Detail & Related papers  (2022-08-23T17:01:16Z)
• Exploring Chemical Space with Score-based Out-of-distribution Generation [57.15855198512551]
  We propose a score-based diffusion scheme that incorporates out-of-distribution control in the generative differential equation (SDE) Since some novel molecules may not meet the basic requirements of real-world drugs, MOOD performs conditional generation by utilizing the gradients from a property predictor. We experimentally validate that MOOD is able to explore the chemical space beyond the training distribution, generating molecules that outscore ones found with existing methods, and even the top 0.01% of the original training pool.
  arXiv  Detail & Related papers  (2022-06-06T06:17:11Z)
• Improved Drug-target Interaction Prediction with Intermolecular Graph Transformer [98.8319016075089]
  We propose a novel approach to model intermolecular information with a three-way Transformer-based architecture. Intermolecular Graph Transformer (IGT) outperforms state-of-the-art approaches by 9.1% and 20.5% over the second best for binding activity and binding pose prediction respectively. IGT exhibits promising drug screening ability against SARS-CoV-2 by identifying 83.1% active drugs that have been validated by wet-lab experiments with near-native predicted binding poses.
  arXiv  Detail & Related papers  (2021-10-14T13:28:02Z)
• Benchmarking Deep Graph Generative Models for Optimizing New Drug Molecules for COVID-19 [11.853524110656991]
  Design of new drug compounds with target properties is a key area of research in generative modeling. We present a small drug molecule design pipeline based on graph-generative models and a comparison study of two state-of-the-art graph generative models for designing COVID-19 targeted drug candidates.
  arXiv  Detail & Related papers  (2021-02-09T17:49:26Z)
• Learn molecular representations from large-scale unlabeled molecules for drug discovery [19.222413268610808]
  Molecular Pre-training Graph-based deep learning framework, named MPG, leans molecular representations from large-scale unlabeled molecules. MolGNet can capture valuable chemistry insights to produce interpretable representation. MPG is promising to become a novel approach in the drug discovery pipeline.
  arXiv  Detail & Related papers  (2020-12-21T08:21:49Z)
• Self-Supervised Graph Transformer on Large-Scale Molecular Data [73.3448373618865]
  We propose a novel framework, GROVER, for molecular representation learning. GROVER can learn rich structural and semantic information of molecules from enormous unlabelled molecular data. We pre-train GROVER with 100 million parameters on 10 million unlabelled molecules -- the biggest GNN and the largest training dataset in molecular representation learning.
  arXiv  Detail & Related papers  (2020-06-18T08:37:04Z)
• CogMol: Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative Models [74.58583689523999]
  We propose an end-to-end framework, named CogMol, for designing new drug-like small molecules targeting novel viral proteins. CogMol combines adaptive pre-training of a molecular SMILES Variational Autoencoder (VAE) and an efficient multi-attribute controlled sampling scheme. CogMol handles multi-constraint design of synthesizable, low-toxic, drug-like molecules with high target specificity and selectivity.
  arXiv  Detail & Related papers  (2020-04-02T18:17:20Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.